2024 Mitsui Chemicals Catalysis Science Awards
1.8.2023 12:00:00 EEST | Business Wire | Press release
Mitsui Chemicals, Inc. (Tokyo: 4183; President & CEO: HASHIMOTO Osamu) today announced that online applications for the 2024 Mitsui Chemicals Catalysis Science Awards will open on September 1, 2023.
Aiming to contribute to the sustainable development of chemistry and the chemical industry, Mitsui Chemicals established the Mitsui Chemicals Catalysis Science Awards in 2004. The awards consist of the Catalysis Science Award and the Catalysis Science Award for Creative Work, which recognize outstanding achievements in the field of catalysis science. To date, the awards have been conferred on 30 researchers within Japan and overseas. The application requirements for the 2024 Mitsui Chemicals Catalysis Science Awards are outlined below.
We welcome applications from a wide range of R&D fields, including solid catalysts, molecular catalysts and biocatalysts, as well as green processes and rare metal utilization via catalysis, along with materials science and development through novel catalysis.
The Mitsui Chemicals Catalysis Science Awards:
https://jp.mitsuichemicals.com/en/techno/csa/index.htm
I. Outline of awards
|
|
Mitsui Chemicals Catalysis Science Award |
Mitsui Chemicals Catalysis Science Award for Creative Work |
|
Eligible applicants |
Researchers affiliated to a university or public research institution, who have demonstrated extraordinary achievements in the field of catalysis science research (prize may be awarded to up to one winner) |
Researchers affiliated to a university or public research institution, who have demonstrated creative achievements in the field of catalysis science research (prize may be awarded to up to two winners) |
|
Application requirements |
Applicants must be no more than 47 years old as of April 1, 2023 |
Applicants must be no more than 37 years old as of April 1, 2023 |
|
Prize |
A plaque and prize money of 5 million yen |
A plaque and prize money of 1 million yen |
II. Schedule and selection process
|
Applications open |
September 1, 2023 |
|
Applications close |
December 31, 2023 |
|
Selection process |
Winners will be chosen by a selection committee organized by Mitsui Chemicals, consisting of several eminent academics in the field of catalysis science and a Mitsui Chemicals representative. |
|
Announcement of winners |
In June 2024 or thereabouts (details will be published on the website and in professional journals, among other sources) |
Please review the information at the link above for further details of the application process, including the application documents and information to be submitted, important notes concerning applications and information on the handling of personal information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230801163348/en/
Contact information
Contacts for inquiries
Corporate Communication Div.
Mitsui Chemicals, Inc.
URL: https://form.mitsuichemicals.com/corporate/cc_pr_csr_en
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boyd Watterson Global Names John Creswell Global Chief Client Officer to Accelerate Global Growth and Client Engagement23.7.2026 16:00:00 EEST | Press release
Boyd Watterson Global today announced the appointment of John Creswell as Global Chief Client Officer, a newly created senior leadership role that reflects the firm's continued investment in growth and its evolution into a leading global alternatives investment platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722823117/en/ John Creswell has joined Boyd Watterson Global as Global Chief Client Officer, a newly created role overseeing global sales, client engagement and marketing across the U.S., Europe and APAC. In this role, Creswell will oversee global sales, client engagement and marketing efforts across the United States, Europe and APAC, helping investors access the firm's capabilities while strengthening relationships with institutional and private capital partners worldwide. While based in Chicago, John will spend considerable time at the firm’s headquarters in Cleveland as well as in key offices globally. Cr
Trulioo Launches AI Agent to Resolve Beneficial Ownership Where Global Registries Fall Short23.7.2026 16:00:00 EEST | Press release
Trulioo, a global risk intelligence platform, today announced the UBO Discovery Agent, the newest layer in Trulioo's UBO Discovery capability inside its business risk and Know Your Business (KYB) verification workflow. AI is reshaping fraud, making it easier for bad actors to hide, and harder for companies to catch them. This makes the already tough job of verifying who actually owns a business even more difficult. Determining a business's ultimate beneficial owner is an ongoing, acute challenge for companies: registry coverage is inconsistent across countries, and even where registries exist, they typically record shareholders and directors of record (rather than the people actually in control). That data isn't simply outdated, it reflects a structural lag: ownership changes and time passes before the filing is made and processed, so a lookup often shows who owned a business months or years ago, not who owns it today. Further, ownership chains that cross borders can break entirely onc
Humanoid Raises $152 Million at $1.35 Billion Post-Money Valuation, Becoming Europe's First Pure-Play Humanoid Robotics Unicorn23.7.2026 16:00:00 EEST | Press release
Humanoid, a UK-based AI and robotics company building industrial humanoid robots, announced a $152 million Series A financing at a $1.35 billion post-money valuation. This funding brings the total amount raised to date to $270 million. The round was led by Prime Movers Lab, a venture capital firm focused on investments in breakthrough scientific startups working to revolutionize the world's most important industries and transform billions of lives, with participation from Schaeffler, Bosch, Fubon Financial Holding Venture Capital, and Aglaé Ventures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260723238282/en/ Humanoid's leadership team with representatives from Prime Movers Lab, the lead investor in Humanoid's Series A financing. Now is a defining moment for the European technology ecosystem which positions the region among the global leaders in one of the world's fastest-growing tech sectors. Until now, much of the Phys
Riskified Named to the CNBC World's Top Fintech Companies 2026 List23.7.2026 15:00:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud detection and risk intelligence, has been named to CNBC's World's Top Fintech Companies 2026 list, in the Payments category. The list, now in its fourth edition, is produced by CNBC in partnership with Statista Inc., the global statistics and industry ranking firm. It was announced on July 22, 2026, and is available on CNBC's website. This is Riskified's second time making the list. The company previously earned this recognition in 2024, reinforcing its position in the ecommerce fraud and risk intelligence sector and underscoring its ongoing success in empowering businesses to grow revenue and profitability by mitigating risk through its AI-powered platform. CNBC and Statista's ranking covers the top 500 companies across eight fintech segments — Payments, Neobanking, Alternative Financing, Wealth Technology, Digital Assets, Enterprise Fintech, Insurtech, and Regtech. Companies are scored using an aggregated model that weighs ov
Azafaros Completes Enrollment of Phase 3 (NAVIGATE) Study Evaluating Nizubaglustat for the Treatment of Patients with GM1/GM2 Gangliosidoses23.7.2026 14:00:00 EEST | Press release
Azafaros, a private company building a portfolio of disease-modifying therapeuticsto become a leader in lysosomal storage disorders (LSDs) focused on addressing neurological symptoms, today announced the completion of patient recruitment in its Phase 3 study evaluating nizubaglustat for the treatment of GM1/GM2 gangliosidoses. “Completing enrollment in our Phase 3 GM1/GM2 study is a significant step toward potentially bringing nizubaglustat to patients and families living with these devastating neurodegenerative diseases," said Stefano Portolano, Chief Executive Officer at Azafaros. "We are deeply grateful to the patients, caregivers, investigators and advocacy groups who have made this milestone possible. As we advance the GM1/GM2 study toward data readout and regulatory submission, we continue to enroll in our Phase 3 NPC study and remain focused on our goal of addressing the significant unmet medical needs faced by these rare disease communities." Professor Roberto Giugliani, Princi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom